Consensus on targeted drug therapy for spondyloarthritis.
10.3760/cma.j.cn112138-20221031-00806
- Collective Name:National Clinical Research Center for Dermatologic and Immunologic Diseases (Peking Union Medical College Hospital);Rheumatology and Immunology Physicians Committee, Chinese Medical Doctors Association;Rheumatology and Immunology Professional Committee, Chinese Association of Rehabilitation Medicine;Chinese Research Hospital Association Rheumatology and Immunology Professional Committee
- Publication Type:Journal Article
- MeSH:
Humans;
Consensus;
Quality of Life;
Spondylarthritis/drug therapy*;
Rheumatology;
Inflammation
- From:
Chinese Journal of Internal Medicine
2023;62(6):606-618
- CountryChina
- Language:Chinese
-
Abstract:
Spondyloarthritis (SpA) is a group of chronic inflammatory conditions that predominantly involve the spine and/or peripheral joints. The clinical manifestations of SpA are diverse and disabling, with SpA adversely affecting the quality of life of patients. Many new medications that target cytokines or pathways specific for the pathogenesis of SpA have been developed and these are becoming increasingly important in the treatment of SpA. However, establishing how to identify the target patient population and standardizing the usage of these drugs are critical issues in the clinical application of these "targeted therapies".Under the leadership of National Clinical Research Center for Dermatologic and Immunologic Diseases (Peking Union Medical College Hospital), the"Consensus on targeted drug therapy for spondyloarthritis" has been developed collaborating with the Rheumatology and Immunology Physicians Committee, Chinese Medical Doctors Association, Rheumatology and Immunology Professional Committee, Chinese Association of Rehabilitation Medicine, Chinese Research Hospital Association Rheumatology and Immunology Professional Committee. This consensus was developed with evidence-based methodology and followed the international standard for consensus development.
